GNPX
Price
$1.99
Change
-$0.06 (-2.93%)
Updated
Oct 22, 04:57 PM (EDT)
Capitalization
1.68M
22 days until earnings call
Intraday BUY SELL Signals
MLEC
Price
$1.64
Change
-$0.02 (-1.20%)
Updated
Oct 22, 04:49 PM (EDT)
Capitalization
1.2M
56 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GNPX vs MLEC

GNPX vs MLEC Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
GNPX vs. MLEC commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GNPX is a StrongBuy and MLEC is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for GNPX with price predictions
Oct 21, 2026

GNPX's RSI Oscillator sits in oversold zone for 5 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +5.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where GNPX advanced for three days, in 148 of 194 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

GNPX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 25, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GNPX as a result. In 67 of 70 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNPX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for GNPX entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.114) is normal, around the industry mean (2.988). P/E Ratio (0.060) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. GNPX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GNPX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for MLEC with price predictions
Oct 21, 2026

MLEC's RSI Indicator sits in oversold zone for 8 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +9.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where MLEC advanced for three days, in 102 of 145 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.

MLEC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for MLEC entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.431) is normal, around the industry mean (2.988). P/E Ratio (-0.006) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.011) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. MLEC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
GNPX: Fundamental Ratings
GNPX
OUTLOOK RATING
1..100
89
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
96
P/E GROWTH RATING
1..100
96
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GNPXMLEC
RSI
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
N/A
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 15 days ago
76%
Bullish Trend 2 days ago
70%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
73%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (GNPX: $2.05 vs. MLEC: $1.66)
Brand notoriety: GNPX and MLEC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GNPX: 152% vs. MLEC: 19%
Market capitalization -- GNPX: $1.62M vs. MLEC: $1.22M
GNPX [@Biotechnology] is valued at $1.62M. MLEC’s [@Biotechnology] market capitalization is $1.22M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GNPX’s FA Score shows that 0 FA rating(s) are green while MLEC’s FA Score has 1 green FA rating(s).

  • GNPX’s FA Score: 0 green, 5 red.
  • MLEC’s FA Score: 1 green, 4 red.
According to our system of comparison, MLEC is a better buy in the long-term than GNPX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GNPX’s TA Score shows that 4 TA indicator(s) are bullish while MLEC’s TA Score has 3 bullish TA indicator(s).

  • GNPX’s TA Score: 4 bullish, 3 bearish.
  • MLEC’s TA Score: 3 bullish, 2 bearish.
According to our system of comparison, both GNPX and MLEC are a good buy in the short-term.

Price Growth

GNPX (@Biotechnology) experienced а -12.02% price change this week, while MLEC (@Biotechnology) price change was -11.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

GNPX is expected to report earnings on Nov 13, 2026.

MLEC is expected to report earnings on Dec 17, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
GNPX
Daily Signal:
Gain/Loss:
MLEC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

GNPX and

Correlation & Price change

A.I.dvisor indicates that over the last year, GNPX has been closely correlated with CANF. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if GNPX jumps, then CANF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GNPX
1D Price
Change %
GNPX100%
-3.76%
CANF - GNPX
93%
Closely correlated
-0.02%
APVO - GNPX
86%
Closely correlated
-0.93%
ICU - GNPX
82%
Closely correlated
+3.93%
MLEC - GNPX
76%
Closely correlated
+3.75%
LONA - GNPX
76%
Closely correlated
+7.59%
More

MLEC and

Correlation & Price change

A.I.dvisor indicates that over the last year, MLEC has been closely correlated with CANF. These tickers have moved in lockstep 89% of the time. This A.I.-generated data suggests there is a high statistical probability that if MLEC jumps, then CANF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLEC
1D Price
Change %
MLEC100%
+3.75%
CANF - MLEC
89%
Closely correlated
-0.02%
APVO - MLEC
79%
Closely correlated
-0.93%
GNPX - MLEC
76%
Closely correlated
-3.76%
LNAI - MLEC
64%
Loosely correlated
+0.58%
LONA - MLEC
58%
Loosely correlated
+7.59%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EGP203.302.05
+1.02%
EastGroup Properties
RBB26.350.22
+0.86%
RBB Bancorp
EFSC60.25-0.30
-0.50%
Enterprise Financial Services Corp
ZYBT1.46-0.03
-2.01%
Zhengye Biotechnology Holding Limited
NIKI1.87-0.16
-7.88%
Niki BioSolutions Inc